Metastatic Colorectal Cancer - prIME Oncology

Metastatic Colorectal Cancer

Highlights From prIME Masterclass in Colorectal Cancer

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Hear from the experts during this webcast that includes highlights from the prIME Masterclass in Colorectal Cancer, recently held in Tokyo. You will have the opportunity to gain valuable insight into the most up-to-date management concepts and emerging treatment strategies for patients with metastatic colorectal cancer (mCRC).

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Jun 14, 2018

Expiration Date

Jun 14, 2019

Can mCRC be cured?
René Adam, MD, PhD

How should we personalize front-line therapy in mCRC?
Kun-Huei Yeh, MD, PhD

The art of continuum of care approach in mCRC and treatment sequencing beyond progression
Takayuki Yoshino, MD, PhD

mCRC in the Coming Years: What Can We Expect?
Scott Kopetz, MD, PhD, FACP

prIME Points™
Scott Kopetz, MD, PhD, FACP

  • René Adam, MD, PhDHepato Biliary Centre at Paul Brousse Hospital
    Villejuif, France
  • Scott Kopetz, MD, PhD, FACPUniversity of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Kun-Huei Yeh, MD, PhDNational Taiwan University Hospital
    National Taiwan University Cancer Center
    Taipei, Taiwan
  • Takayuki Yoshino, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals involved in the management of CRC.

After successful completion of this educational activity, participants should be able to:

  • Explain state-of-the-art management of early and mCRC, and evaluate current and emerging biomarkers to guide personalized therapy
  • Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
  • Select optimal front-line treatment for mCRC and assess sequencing strategies beyond disease progression
  • Evaluate treatment options for metastatic BRAF-mutant mCRC
  • Describe emerging agents in mCRC, including immunotherapy-based combinations

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Adam has disclosed that he has received fees for speaking and teaching from Amgen, Merck, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kopetz has disclosed that he has received consulting fees from Amgen, Array, Bayer, Genentech, and Taiho. He also has ownership interest in MolecularMatch. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yeh has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yoshino has disclosed that he has received honorarium for promotional speaker’s bureaus from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceuticals Co., Ltd, and Eli Lilly Japan K.K. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.